Your browser doesn't support javascript.
Ibuprofen use and clinical outcomes in COVID-19 patients.
Rinott, E; Kozer, E; Shapira, Y; Bar-Haim, A; Youngster, I.
  • Rinott E; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Kozer E; Paediatric Emergency Unit, Shamir (Assaf Harofeh) Medical Centre, Zerifin, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Shapira Y; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Division of Internal Medicine, Shamir (Assaf Harofeh) Medical Centre, Zerifin, Israel.
  • Bar-Haim A; Molecular Laboratory, Shamir (Assaf Harofeh) Medical Centre, Zerifin, Israel.
  • Youngster I; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Paediatric Infectious Diseases, Shamir (Assaf Harofeh) Medical Centre, Zerifin, Israel. Electronic address: youngsteri@shamir.gov.il.
Clin Microbiol Infect ; 26(9): 1259.e5-1259.e7, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-597470
ABSTRACT

OBJECTIVE:

It was recently suggested that ibuprofen might increase the risk for severe and fatal coronavirus disease 2019 (COVID-19) and should therefore be avoided in this patient population. We aimed to evaluate whether ibuprofen use in individuals with COVID-19 was associated with more severe disease, compared with individuals using paracetamol or no antipyretics.

METHODS:

In a retrospective cohort study of patients with COVID-19 from Shamir Medical Centre, Israel, we monitored any use of ibuprofen from a week before diagnosis of COVID-19 throughout the disease. Primary outcomes were mortality and the need for respiratory support, including oxygen administration and mechanical ventilation.

RESULTS:

The study included 403 confirmed cases of COVID-19, with a median age of 45 years. Of the entire cohort, 44 patients (11%) needed respiratory support and 12 (3%) died. One hundred and seventy-nine (44%) patients had fever, with 32% using paracetamol and 22% using ibuprofen, for symptom-relief. In the ibuprofen group, 3 (3.4%) patients died, whereas in the non-ibuprofen group, 9 (2.8%) patients died (p 0.95). Nine (10.3%) patients from the ibuprofen group needed respiratory support, compared with 35 (11%) from the non-ibuprofen group (p 1). When compared with exclusive paracetamol users, no differences were observed in mortality rates or the need for respiratory support among patients using ibuprofen.

CONCLUSIONS:

In this cohort of COVID-19 patients, ibuprofen use was not associated with worse clinical outcomes, compared with paracetamol or no antipyretic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ibuprofen / Fever / COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2020 Document Type: Article Affiliation country: J.cmi.2020.06.003

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Ibuprofen / Fever / COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2020 Document Type: Article Affiliation country: J.cmi.2020.06.003